Streetbeat News

Products Services

TVTX

Travere Therapeutics' shares rose following FDA's full approval of FILSPARI for treating primary IgAN. HC Wainwright & Co also maintained a Buy rating and increased the price target from $20 to $23.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:32 am

BLMZ

BloomZ Inc. (NASDAQ:BLMZ) shares surged premarket after announcing a partnership with CrossVision Inc., a Japanese digital entertainment company. The collaboration aims to integrate BloomZ's animation expertise with CrossVision's Web 3.0 technology to enhance fan engagement through blockchain and metaverse events.

Portfolio Pulse from Lekha Gupta

September 06, 2024 | 11:23 am

AXGN

Axogen has completed the submission of a Biologics License Application to the FDA for its Avance Nerve Graft, a significant step in the regulatory process for the product.

Portfolio Pulse from Nabaparna Bhattacharya

September 06, 2024 | 11:10 am

MIST

Milestone Pharmaceuticals announced that its licensing partner, Ji Xing, has released positive topline results from a trial in China for Etripamil nasal spray. The trial met its primary endpoint, indicating potential success for the product.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 11:04 am

GSK

VRNA

GSK's asthma drug Nucala met its primary goal in a Phase 3 trial for COPD, showing significant reduction in exacerbations. This positions GSK to compete with Amgen/AstraZeneca's similar drug. Nucala is not yet approved for COPD, but the trial results may influence future regulatory discussions.

Portfolio Pulse from Vandana Singh

September 06, 2024 | 10:56 am

HUT

Hut 8 Mining Corp. has released its operations update for August 2024, highlighting that it manages 18.5 EH/s and 762 MW in mining. The company is also advancing commercialization efforts for a 205MW site in the Texas Panhandle.

Portfolio Pulse from Nabaparna Bhattacharya

September 06, 2024 | 10:40 am

KALV

KalVista Pharmaceuticals presented new analyses on the efficacy and safety of Sebetralstat, an investigational treatment for hereditary angioedema, at the Bradykinin Symposium 2024. The data includes results from Phase 2 and Phase 3 trials, as well as interim data from an open-label extension trial.

Portfolio Pulse from Nabaparna Bhattacharya

September 06, 2024 | 10:35 am

FANH

Fanhua's subsidiary, Fanhua BluePlus, has signed a strategic cooperation agreement with Shanghai Biotecan Pharmaceuticals. The collaboration will focus on medical testing, health management, and cell therapy services.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2024 | 10:32 am

CRM

FEPI

IGV

Salesforce is acquiring Own Company for $1.9 billion to enhance its data security offerings. The acquisition is expected to close in Salesforce's fiscal year 2025 and will be accretive to free cash flow in the second year post-closing. Salesforce also declared a quarterly dividend and reported strong Q2 earnings.

Portfolio Pulse from Lekha Gupta

September 06, 2024 | 10:04 am

AVGO

QQQ

SPY

US stocks are set for a decline amid anxiety over upcoming jobs data, with the VIX index surging. Broadcom's soft guidance is impacting its stock and peers. The SPDR S&P 500 ETF and Invesco QQQ ETF are also down in premarket trading.

Portfolio Pulse from Shanthi Rexaline

September 06, 2024 | 10:04 am